Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

No respite for Indian indices
Wed, 11 Dec Closing

Indian equity markets began the day's proceedings on a weak note and languished in the red throughout today's session as selling activity persisted across index heavyweights. There was no respite in the final trading hour either and indices closed well below the dotted line. While the BSE-Sensex today closed lower by 84 points, the NSE-Nifty closed lower by 25 points. While the BSE Mid Cap closed weak, the BSE Small Cap bucked the trend and gained marginally. Losses were largely seen in metals and oil & gas stocks.

As regards global markets, most Asian indices closed weak today while European indices have opened mixed. The rupee was trading at Rs 61.31 to the dollar at the time of writing.

Pharma stocks closed mixed today. While Lupin and Ranbaxy closed firm, Biocon and Wockhardt led the pack of losers. As per a leading business daily, Lupin has received US FDA approval to market generic version of ViiV Healthcare's Trizivir tablets in the US market. This drug is indicated for the treatment of HIV-1 infection. Because the company was the first-to-file (FTF) for this product, it will be entitled to 180 days market exclusivity. According to IMS MAT September 2013 sales data, Trizivir tablets has US sales of around US$ 111.6 m. This is a positive for the company and will enhance its sales from the highly competitive US generics market. Because of the exclusivity period, the revenue and profit potential will be higher because it will be the only player in the market besides the innovator. Lupin has been doing well in the US, which can be gauged by the fact that it is the market leader in 26 products out of the 57 that have been launched in this market.

Auto stocks also closed mixed today. While Ashok Leyland and Bajaj Auto found favour, Tata Motors and Hero Motocorp closed into the red. There was no respite for the Indian auto industry in the month of November 2013 as volumes across most segments saw a decline. While passenger cars were down 8% YoY during the month, the fall in commercial vehicles (CV) volumes was even steeper at 29% YoY. Utility vehicles, which were the star performers in FY13, also saw volumes fall by 9% YoY. Slowdown in the economy coupled with firm interest rates and fuel prices have taken its toll on demand. Much hope was pinned on the festive season, which failed to live upto expectations. The outlook for the rest of FY14 remains tepid. However, there are hopes that if the economy displays signs of recovery in FY15, this should rub off positively on the beleaguered auto industry as well.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary


What else is happening in the markets today? Dig in...

Equitymaster requests your view! Post a comment on "No respite for Indian indices". Click here!

  

Related Views on News

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market (Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

I Believe the Investment of the Year Will Be...

Feb 19, 2021

In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.

The Hidden Tesla in My Great Indian Wealth Project (Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Mar 2, 2021 (Close)

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS